Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer

Inclusion Criteria: * Male 18 years and older * Histologically confirmed prostate adenocarcinoma Stage pathological tumor-2 (pT2) * Post radical Primary Prostatectomy * Completion of DCVAC/PCa arm in Study SP003, without objective progression of the disease Exclusion Criteria: * Prior androgen deprivation therapy for prostate cancer * Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater * Other uncontrolled intercurrent illness * Treatment with immunotherapy against PCa * Clinically significant cardiovascular disease * Active autoimmune disease requiring treatment